ValiRx PLC US Patent Grant re VAL201 & Metastatic Cancer (9120U)
28 Novembre 2019 - 08:00AM
UK Regulatory
TIDMVAL
RNS Number : 9120U
ValiRx PLC
28 November 2019
VALIRX PLC
("ValiRx", the "Company" or the "Group")
US PATENT GRANT
FOR THE USE OF VAL201 IN THE PREVENTION AND TREATMENT
OF METASTATIC CANCER
London, UK., 28 November 2019: ValiRx Plc (AIM: VAL), the
clinical stage biotechnology company, announces that the US Patent
and Trademark Office has granted the US Patent No. 10,400,008 and
title: "Modulators Of The SRC-Kinase Activity For Preventing Or
Treating Metastatic Cancer", to the Company's lead therapeutic
compound, VAL201. The grant provides patent protection for a method
of preventing the worsening of symptoms of a metastatic cancer,
reducing the progression of a metastatic cancer, or treating a
metastatic cancer (including prostate cancer) by administration of
the VAL201 peptide. This follows the Company's earlier announcement
on 26 June 2019, regarding its receipt of a US Patent Notice of
Allowance for the use of VAL201 in the prevention and treatment of
metastatic cancer.
Metastatic cancer is classified when the disease spreads beyond
the primary tumour to other parts of the body. This spread is known
as metastatic disease and in prostate cancer it commonly spreads to
the bones and lymph nodes. The main goals for treatment of
metastatic cancer are symptom control, slowing or stopping the rate
at which the cancer grows, as well as targeting the underlying
cancer.
ValiRx's VAL201 compound selectively prevents tumour growth by
specifically inhibiting the proliferation of tumour cells. Its
inhibitory effects on lymph node metastases have been demonstrated
in pre-clinical prostate cancer models. The compound is currently
in a Phase I/II study primarily assessing the safety and
tolerability of VAL201 and its effect in the treatment of prostate
cancer and other solid tumours. The trial of VAL201 has met its
endpoints very well and the Company is now able to use the peptide
in demonstrating the efficacy of the compound as a therapeutic
product, addressing what is currently a poorly-served, yet very
substantial commercial market.
Dr Satu Vainikka, CEO of ValiRx, commented: "Since all primary
cancers will metastasise and can spread anywhere around the body at
some point, this US patent grant, covering one of our largest
commercial markets, represents a key addition to our patent
coverage and protection for this indication. I look forward to the
further development of the VAL201 compound and the validation of
its potential anti-cancer impact".
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
*** ENDS ***
For more information, please contact:
ValiRx plc Tel: +44 (0) 20 3008 4416
www.valirx.com
Dr Satu Vainikka, Chief Executive Tel: +44 (0) 20 3008 4416
Tarquin Edwards, Head of Communications. Tel: +44 (0) 7879 458
364
tarquin.edwards@valirx.com
Cairn Financial Advisers LLP (Nominated Tel: +44 (0) 20 7213 0880
Adviser)
Liam Murray / Jo Turner / Ludovico
Lazzaretti
Allenby Capital Limited (Joint Broker) Tel: +44 (0) 20 3328 5656
Jeremy Porter / Alex Brearley (Corporate
Finance)
Kelly Gardiner (Equity Sales)
Novum Securities Limited (Joint Broker) Tel: +44 (0) 20 7399 9400
Colin Rowbury
Notes for Editors
About ValiRx
ValiRx is a biotechnology oncology focused company specialising
in developing novel treatments for cancer and associated
biomarkers. It aims to make a significant contribution in
"precision" medicine and science, namely to engineer a breakthrough
into human health and well-being, through the early detection of
cancer and its therapeutic intervention.
The Company's business model focuses on out-licensing
therapeutic candidates early in the development process. By aiming
for early-stage value creation, the company reduces risk
considerably while increasing the potential for realising value.
The group is already in licensing discussions with major players in
the oncology field.
ValiRx's two classes of drugs in development, which each have
the potential for meeting hitherto unmet medical needs by existing
methods, have worldwide patent filings and agreed commercial
rights. They originate or derive from World class institutions,
such as Cancer Research UK and Imperial College.
Until recently, cancer treatments relied on non-specific agents,
such as chemotherapy. With the development of target-based agents,
primed to attack cancer cells only, less toxic and more effective
treatments are now possible. New drugs in this group-such as those
in ValiRx's pipeline-promise to greatly improve outcomes for cancer
patients.
The Company listed on the AIM Market of the London Stock
Exchange in October 2006 and trades under the ticker symbol:
VAL.
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identi ed by their use of terms and phrases such as "believe",
"could", "should" "envisage", "estimate", "intend", "may", "plan",
"potentially", "expect", "will" or the negative of those,
variations or comparable expressions, including references to
assumptions. These forward looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Such
forward looking statements re ect the Directors' current beliefs
and assumptions and are based on information currently available to
the Directors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCVDLFLKFFBFBE
(END) Dow Jones Newswires
November 28, 2019 02:00 ET (07:00 GMT)
Grafico Azioni Valirx (LSE:VAL)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Valirx (LSE:VAL)
Storico
Da Mar 2023 a Mar 2024